

UCSF Health Guidance for Discontinuing Isolation for Select Severely Immunocompromised COVID+ Patients

Guidelines are intended to assist with clinical decision-making but cannot replace personalized evaluation and management decisions based on individual patient factors

Select severely immunocompromised

All patients

1. Solid organ transplant recipient in the last year
2. Receiving rituximab or other B-cell depleting agents within the last 6 months
3. Primary immunodeficiencies - combined immunodeficiencies (e.g. SCID/CVID), B-cell deficiencies and/or needing immunoglobulin replacement, idiopathic CD4 lymphopenia/severe lymphopenia; but NOT CGD or most DiGeorge's syndrome

a. Adult services

- i. Adult AML/ALL until 3 months after completion of cytotoxic chemotherapy
- ii. Adult CAR-T cell and Allogeneic stem cell transplant within last 3 months

b. Pediatric services

- i. Patients with AML until 3 months after completion of chemotherapy
- ii. Patients with infant ALL and/or ALL patients not in remission
- iii. Patients with CAR-T cell therapy within the last 3 months
- iv. All BMT patients without T cell reconstitution

Otherwise refer to the general discontinuation guidance for COVID-19 positive patients

COVID-19 positivity should not delay time-sensitive care

Hospital Epidemiology and Infection Prevention (HEIP) Moffitt-Long and Mt.Zion Business Hours
415-353-4343 or 415-806-0269 (cell) or via Voalte 'Adult infection preventionist on call'

Mission Bay Business Hours
415-866-9242 or 415-806-0269 (cell) or via Voalte 'Peds infection preventionist on call'

